JISTIC: identification of significant targets in cancer. (scientific article)

Identification and characterization of EBP, a novel EEN binding protein that inhibits Ras signaling and is recruited into the nucleus by the MLL-EEN fusion protein

Q28208684

Multiple recurrent genetic events converge on control of histone lysine methylation in medulloblastoma

Q28237604

CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity

Q28294122

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

Q30014823

Analysis of array CGH data: from signal ratio to gain and loss of DNA regions

Q30961366

Functional copy-number alterations in cancer

Q33368629

Microarray analysis reveals a major direct role of DNA copy number alteration in the transcriptional program of human breast tumors

Q34190883

Gene expression profiling separates chromophobe renal cell carcinoma from oncocytoma and identifies vesicular transport and cell junction proteins as differentially expressed genes.

Q34587288

Nuclear factor 45 (NF45) is a regulatory subunit of complexes with NF90/110 involved in mitotic control

Q36748114

Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling

Q36802989

Fibulin 1 is downregulated through promoter hypermethylation in gastric cancer

Q37023915

Integrated genomic profiling of endometrial carcinoma associates aggressive tumors with indicators of PI3 kinase activation

Q37140110

Loss of alpha-dystroglycan laminin binding in epithelium-derived cancers is caused by silencing of LARGE.

Q37160880

The urokinase receptor and its structural homologue C4.4A in human cancer: expression, prognosis and pharmacological inhibition

Q37294301

Polypyrimidine tract binding protein regulates IRES-mediated gene expression during apoptosis

Q38310976

A CD147-targeting siRNA inhibits the proliferation, invasiveness, and VEGF production of human malignant melanoma cells by down-regulating glycolysis

Q39941968

Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia with TCL1A-TCRAD juxtaposition

Q47694238

P275

Creative Commons Attribution 2.0 Generic

copyrighted

page(s)

189

P577

publication date

2010-04-14

P1433

published in

BMC Bioinformatics

Q4835939

P1476

title

JISTIC: identification of significant targets in cancer

P478

volume

Reverse relations

cites work (P2860)

Q30654515	A genomic random interval model for statistical analysis of genomic lesion data
Q30570534	A high-throughput computational framework for identifying significant copy number aberrations from array comparative genomic hybridisation data
Q39896921	A method for generating new datasets based on copy number for cancer analysis
Q40366176	A scale-space method for detecting recurrent DNA copy number changes with analytical false discovery rate control
Q28394747	A systematic comparison of copy number alterations in four types of female cancer
Q34453995	An integrated approach to uncover drivers of cancer.
Q28487526	An integrative genomic and transcriptomic analysis reveals potential targets associated with cell proliferation in uterine leiomyomas
Q34534035	Comparative analysis of methods for identifying recurrent copy number alterations in cancer
Q34979403	Comparative oncogenomic analysis of copy number alterations in human and zebrafish tumors enables cancer driver discovery
Q41145800	DEOD: uncovering dominant effects of cancer-driver genes based on a partial covariance selection method
Q38265995	Deciphering oncogenic drivers: from single genes to integrated pathways
Q33760431	Detecting independent and recurrent copy number aberrations using interval graphs
Q35557782	GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers
Q55714851	Germline and somatic variations influence the somatic mutational signatures of esophageal squamous cell carcinomas in a Chinese population.
Q38645510	Hypodontia, a prospective predictive marker for tumor?
Q89077811	Identifying disease-associated copy number variations by a doubly penalized regression model
Q37689928	Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine
Q50088009	Ligand-activated BMP signaling inhibits cell differentiation and death to promote melanoma.
Q43090167	MelanomaDB: A Web Tool for Integrative Analysis of Melanoma Genomic Information to Identify Disease-Associated Molecular Pathways
Q99350211	Probability distribution of copy number alterations along the genome: an algorithm to distinguish different tumour profiles
Q37248289	RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation
Q39616819	RUBIC identifies driver genes by detecting recurrent DNA copy number breaks
Q35008652	SubPatCNV: approximate subspace pattern mining for mapping copy-number variations
Q35032523	The landscape of candidate driver genes differs between male and female breast cancer
Q42182370	Trans-ancestry mutational landscape of hepatocellular carcinoma genomes
Q36833326	Transposon mutagenesis identifies genetic drivers of Braf(V600E) melanoma
Q35051828	Uncover disease genes by maximizing information flow in the phenome-interactome network

P8978	DBLP publication ID	journals/bmcbi/Sanchez-GarciaAMP10
P6179	Dimensions Publication ID	1011737467
P356	DOI	10.1186/1471-2105-11-189
P2888	exact match	https://scigraph.springernature.com/pub.10.1186/1471-2105-11-189
P932	PMC publication ID	2873534
P698	PubMed publication ID	20398270
P5875	ResearchGate publication ID	43180903